Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$980.16 USD
+10.25 (1.06%)
Updated May 31, 2024 04:00 PM ET
After-Market: $980.30 +0.14 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Brokerage Reports
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 381 - 400 ( 591 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupilumab Positive Phase III Data - Buy
Provider: G.RESEARCH, LLC
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Skin Feels So Good; Dupilumab Wins in Atopic Dermatitis
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Praluent Patent Litigation
Provider: G.RESEARCH, LLC
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating our coverage on Regeneron with a Buy recommendation and a 2017 PMV of $574 per share.
Provider: G.RESEARCH, LLC
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MONARCH Puts The Crown On;Sarilumab > Humira; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Too Much Going On to Ignore the Value Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Market Turbulence Provides Strong Opportunity; Upgrade to Buy and $555 PT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sarilumab Prospects in RA - New Praluent Post-Hoc Analyses
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J